The transfer of drug resistance genes into hematopoietic cells is an experimental approach to protect patients from drug-induced myelosuppression. Because anti-cancer drugs are often administered in combination to increase their clinical efficacy, vectors that express two drug resistance genes are being developed to broaden the spectrum of chemoprotection. We have constructed a bicistronic vector, MFG/GST-IRES-CD (MFG/GIC) coexpressing rat glutathione S-transferase (GST) A3 isoform (rGST Yc 1 ) and human cytidine deaminase (CD). Murine NIH 3T3 fibroblast cells transduced with this vector were evaluated for their resistance to nitrogen mustards and cytosine nucleoside analogs. GIC-transduced polyclonal cell populations (GIC cells) demonstrated marked increases in selenium-independent glutathione peroxidase (peroxidase) and CD activities, as well as increased resistance to melphalan (2.3-fold), chlorambucil (3.4-fold), and cytosine arabinoside (Ara-C) (8.1-fold). After selection with Ara-C, the peroxidase and CD activities of GIC cells were augmented 2.6-and 2.9-fold, respectively, in comparison with unselected cells, and the resistance to melphalan, chlorambucil, and Ara-C was further increased to 3.7-, 5.9-, and 53-fold, respectively. Melphalan selection of GIC cells likewise augmented their peroxidase (2.3-fold) and CD (1.9-fold) activities. GIC cells proliferated in the simultaneous presence of melphalan and Ara-C at drug concentrations that completely inhibited the growth of untransduced cells. The growth rate of unselected GIC cells exposed to the drug combination averaged 18% that of drug-free cultures. The growth rate of GIC cells exposed to the drug combination increased to 30% of controls after Ara-C selection and to 50% after melphalan selection. Our results suggest that retroviral transfer of MFG/GIC may be useful for chemoprotection against the toxicities of nitrogen mustards and cytosine nucleoside analogs. Cancer Gene Therapy (2000) 7, 757-765
S ystemic treatment with cytotoxic drugs is the basis of most effective treatments for disseminated cancers. However, the effectiveness of systemic chemotherapy is greatly limited by acute dose-limiting toxicities, principally myelosuppression. Current measures to circumvent this limitation, such as the use of hematopoietic growth factor support, pharmacological rescue, and hematopoietic cell transplantation, do not entirely eliminate the hematopoietic toxicity and may not protect from multiple cycles of high dose chemotherapy. The introduction of drug resistance genes into hematopoietic cells may increase the bone marrow tolerance to chemotherapy and may permit safer dose escalation to increase clinical efficacy (reviewed in Refs. [1] [2] [3] . The feasibility of this approach has been validated in murine animal models for the following genes: multidrug resistance (MDR1), 4 ,5 dihydrofolate reductase (⌬DHFR), 6 ,7 methylguanine methyltransferase (MGMT), 8, 9 and alkyltransferase (ada). 10 On the basis of these preclinical studies, clinical trials have begun in cancer patients with the introduction of MDR1 and MGMT genes into hematopoietic progenitor cells. [11] [12] [13] Glutathione S-transferases (GSTs) represent a family of multifunctional cellular homodimer and heterodimer proteins that detoxify and enhance the cellular efflux of a wide range of xenobiotics and metabolites. GSTs catalyze the conjugation of electrophilic compounds to the tripeptide glutathione (GSH) and are capable of binding directly to nonsubstrate lypophilic substances. Some members of the family possess significant peroxidase activity, which may enable them to detoxify lipid and nucleic acid hydroperoxides resulting from drug exposure. Overexpression of the GST ␣ isoenzymes has been implicated in resistance to nitrogen mustards. 14 Our laboratory has been investigating the rat GST A3 gene (previously designated GST Yc 1 ), a member of the ␣ family of GSTs characterized by a high organic peroxidase activity. 15 The highest level of resistance demonstrated to nitrogen mustards to date has been obtained after gene transfer of the rat GST A3 isoform. 16 We have shown, in previous studies, that retroviral gene transfer of this isoform confers in vitro resistance to nitrogen mustards in human K-562 cells and in murine fibroblasts and bone marrow-derived hematopoietic progenitor cells. 17, 18 We have also studied the human drug resistance gene cytidine deaminase (CD), which catalyzes the deamination of cytidine and deoxycytidine to uridine and deoxyuridine, respectively. We have demonstrated an increased in vitro resistance to the cytosine nucleoside analogs gemcitabine, decitabine, and cytosine arabinoside (Ara-C) in murine fibroblasts after retroviral gene transfer of CD. 19, 20 We have also shown increased in vitro resistance to Ara-C in murine bone marrow progenitor cells transduced with CD 20 and have recently demonstrated long-term expression of CD in hematopoietic cells of transplanted mice. 21 Because anti-cancer drugs are usually given in combination to increase their efficacy and limit the development of drug resistance in tumor cells, designing vectors that coexpress drug resistance genes for two distinct classes of drugs should be useful for the purpose of hematopoietic chemoprotection. A number of studies have demonstrated the feasibility of combining drug resistance mechanisms for the purpose of chemoprotection. Resistance to P-glycoprotein effluxed drugs and antifolates or nitrosoureas was obtained by coexpression of MDR1 and ⌬DHFR 22 or MGMT genes. 23 Resistance to antifolates and fluoropyrimidine has been demonstrated by coexpression of ⌬DHFR and thymidylate synthase genes. 24 We have recently shown resistance to antifolates and cytosine nucleoside analogs by coexpression of ⌬DHFR and CD in murine fibroblasts and bone marrow progenitor cells. 25 In the present study, we have combined the expression of the rat GST A3 (GST) and human CD genes in a bicistronic retroviral vector, MFG/GST-IRES-CD (MFG/GIC), in which translation of the GST cDNA is cap-dependent and translation of the CD cDNA is dependent upon an internal ribosome entry site (IRES). Murine fibroblasts transduced with MFG/GIC displayed resistance to nitrogen mustards and Ara-C administered separately or in combination. Selection of transduced cells with Ara-C or melphalan augmented their levels of resistance to both classes of drugs, separately and in combination. Our results suggest that retroviral transfer of MFG/GIC may be useful for chemoprotection against the combined toxicities of nitrogen mustards and cytosine nucleoside analogs. Our results also suggest that MFG/GIC-mediated chemoprotection may be further increased after selection with either class of drugs. This may be particularly useful to increase the level of chemoprotection from the widely used nitrogen mustards.
MATERIALS AND METHODS

Cell lines
NIH 3T3 (3T3) mouse fibroblasts and virus-producing cells derived from GPϩE-86 and GPϩenvAm-12 packaging cells 26, 27 were maintained in Dulbecco's modified Eagle's medium (Biomedia, Drummondville, Québec, Canada) supplemented with 10% heat-inactivated fetal bovine sera (Biomedia) and 5 g/mL gentamicin (Boehringer Mannheim, Laval, Québec, Canada) at 37°C in a 5% CO 2 incubator.
Vector constructions
Rat GST cDNA was inserted into the MFG expression retrovirus vector at the position of the viral env initiation codon. A 986-bp fragment comprising the last 299 bp preceding the env initiation codon of MFG and the complete GST cDNA (665 bp) was constructed by polymerase chain reaction (PCR) using two different templates and three amplification reactions. First, the region of MFG preceding the env initiation codon (3ЈMFG) was amplified from pMFG-tPA (obtained from R. Mulligan, Whitehead Institute, Cambridge, Mass) with the sense oligonucleotide primer 5Ј-GCCATACGCCAACCCTCTCTCCA-AGC-3Јandtheantisenseprimer5Ј-GCTTCCCCGGCATGGCA-GTCTAGAG-3Ј; the latter included the 5Ј end of GST (underlined in the sequence). Second, the cDNA of GST was amplified from pPSMYc 17 using the sense primer 5Ј-CCATC-CTCTAGACTGCCATGCCGGG-3Ј and the antisense primer 5Ј-CCCCATCCGCGGTTAACTGAAGATCTTAA-3Ј; the underlined sequences correspond to the vector sequence preceding the viral env initiation codon of MFG, including a SacII restriction site. These amplification reactions yielded products of 324 bp and 694 bp, respectively. A total of 25 ng of pMFG-tPA and 10 ng of pPSMYc were amplified in a final volume of 50 L of 50 mM KCl, 10 mM tris(hydroxymethyl)aminomethane-Cl (pH 8.4), 0.1 mg/mL gelatin, 0.4 mM each of deoxyadenosine triphosphate, deoxycytidine triphosphate, deoxyguanosine triphosphate, and deoxythymidine triphosphate, 0.5 pM of each oligonucleotide primer, and 2 U of ID-Proof (Taq) DNA polymerase (ID Labs Biotechnology, London, Ontario, Canada). The samples were heated at 94°C for 6 minutes, during which 3 mM MgCl 2 was added. The samples were then amplified for 20 cycles, with each cycle consisting of 1 minute at 94°C for denaturation, 1 minute at 55°C for annealing, and 1 minute 45 seconds at 72°C for extension, with a terminal extension of 7 minutes at 72°C. The complete 3ЈMFG/GST fragment was amplified with the same reaction conditions using the 3ЈMFG and GST PCR products as templates. The 20-bp homology between the two templates allows efficient amplification when using the sense primer of the 3ЈMFG amplification and the antisense primer of the GST amplification. A total of 10 ng of each template was amplified for 22 cycles, with the first two cycles being performed in the absence of primers. The 3ЈMFG/GST fragment was then digested with SacII, gel purified, and ligated with pBluescript II KS ϩ (Stratagene, La Jolla, Calif) that had been digested previously with SacI, blunted, digested again with SacII, and purified on gel. The integrity of the PCR component was confirmed by se-quencing (with a Pharmacia automatic DNA sequencer; Pharmacia, Baie d'Urfé, Québec, Canada). Finally, the plasmids Bluescript/3ЈMFG/GST and MFG-tPA were digested with AgeI plus BamHI; the fragments 3ЈMFG/GST and pMFG were gel purified and ligated together to generate pMFG/GST (Fig 1) .
To construct pMFG/GIC, pBluescript/3ЈMFG/GST was digested with SacII plus BamHI and gel purified; next, the 3ЈMFG/GST fragment was ligated with the IRES-CD fragment that had been released and gel purified from a SacII plus BamHI digest of pMFG-DHFR-IRES-CD. 25 The plasmids MFG-tPA and Bluescript/3ЈMFG/GIC were then digested with AgeI plus BamHI and gel purified; the fragments pMFG and 3ЈMFG/GIC were ligated together to obtain pMFG/GIC (Fig 1) .
The construction of pMFG/CD has been described previously (Fig 1) . 20 
Generation of virus-producing cells
The plasmid pMFG/GST was cotransfected in a 10:1 molar ratio with pSV2neo 28 into GPϩenvAm-12 amphotropic packaging cells using a polycationic reagent (SuperFect; Qiagen, Chatsworth, Calif). Stable transfectants were selected with G418 (Geneticin; Life Technologies, Burlington, Ontario, Canada), a neomycin analog, at 300 mg/mL (active drug), starting at 48 hours posttransfection. For 10 consecutive days, GPϩE-86 ecotropic packaging cells were supplied with filtered supernatant from the G418-resistant polyclonal population of amphotropic producers, supplemented with 4 g/mL polybrene (Sigma, St. Louis, Mo). The ecotropic virus producers were then cocultivated with amphotropic packaging cells in a 1:1 ratio for 21 days. The GPϩenvAm-12/GST polyclonal population was finally isolated by selection with 200 g/mL hygromycin. 29 The plasmid pMFG/GIC was cotransfected in a 5:1 molar ratio with pSV2neo into GPϩenvAm-12 cells by calcium phosphate precipitation (Pharmacia), and stable transfectants were selected with 300 mg/mL G418. Filtered supernatant from the G418-resistant polyclonal population was supplemented with 8 g/mL polybrene and applied over GPϩE-86 cells for 3 consecutive days. The ecotropic virus producers were selected for 4 days in 2.5 M Ara-C (Sigma) and subsequently cocultivated with amphotropic packaging cells in a 1:1 ratio for 21 days. Again, the GPϩenvAm-12/GIC polyclonal population was selected with 200 g/mL hygromycin (titer, 4.0 ϫ 10 5 viral particles/mL). The generation of the ecotropic CD producer clone GPϩE-86/CD3 has been described previously. 20 Transduction of 3T3 cells and drug selection 3T3 cells were transduced with filtered supernatant from GPϩenvAm-12/GST and GPϩenvAm-12/GIC virus producers supplemented with 8 g/mL polybrene for 3 consecutive days to generate NIH/GST (GST) and NIH/GIC (GIC) polyclonal unselected populations. Filtered supernatant from GPϩE-86/ CD3 virus producers supplemented with 4 g/mL polybrene was applied on 3T3 cells for 5 consecutive days to generate the NIH/CD (CD) polyclonal population.
A total of 300,000 CD and GIC cells were plated in 80-cm 2 tissue culture flasks and selected with 10 M Ara-C for 4 days. GST and GIC cells were selected with 25 M melphalan under the same conditions. The cells were trypsinized and plated in fresh medium after selection.
Southern blot analysis
Genomic DNA extraction and Southern blots were performed as described previously. 17 Genomic DNA samples were digested with SacI, migrated on a 1% agarose gel, and transferred to a nylon membrane. The NcoI/BamHI fragment of pMFG/CD (containing the full-length CD cDNA) was radiolabeled by random primer and hybridized with the membrane. To determine the copy number of CD-containing vectors in genomic DNA, graded quantities of the MFG/CD plasmid were added to 10 g of genomic DNA from 3T3 cells followed by digestion with SacI.
Enzyme assays
Separate cytosolic extracts were prepared for each independent assay by cell lysis in water and centrifugation of debris at 3300 ϫ g for 30 minutes at 4°C. Protein concentrations were determined according to the method of Bradford with the Bio-Rad Protein Assay (Bio-Rad Laboratories, Mississauga, Ontario, Canada) using bovine sera albumin as a standard. The peroxidase assay was performed using 1.5 mM cumene hydroperoxide as the substrate. 30 The reaction mixture was prepared fresh for each assay and consisted of 50 mM potassium phosphate buffer (pH 7.4), 1.0 mM ethylenediaminetetraacetic acid, 1.0 mM sodium azide, 1.0 mM GSH (reduced form; Sigma), 0.2 mM reduced nicotinamide-adenine dinucleotide phosphate (Boehringer Mannheim), and 1 U/mL GSH reductase (Boehringer Mannheim). Samples (400 -800 L) were preincubated at 37°C for 5 minutes and then mixed with 100 L of reaction mixture and 100 L of cumene hydroperoxide in a total volume of 1.0 mL. Absorbance at 340 nm was recorded for 5 minutes, and the activity was expressed as nanomoles of reduced nicotinamide-adenine dinucleotide phosphate oxidized per minute per milligram of protein over the linear range. CD activity was determined by measuring the conversion of [ 3 H]cytidine to [ 3 H]uridine, as described previously.
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Figure 1. Retroviral vector constructions are based on the Moloney murine leukemia virus. MFG-GST contains rat GST A3 cDNA and MFG-CD contains human CD cDNA. The bicistronic vector MFG/ GIC contains rat GST A3 cDNA and human CD cDNA. In MFG/GIC, both gene products are generated from a single long terminal repeat (LTR)-initiated transcript, using cap-independent translation of the second gene that is preceded by the IRES of a picornavirus. The location of the SacI restriction enzyme sites used in the Southern blot analysis are shown, as well as the sites used for vector construction. This figure is not drawn to scale.
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay
The drug sensitivity of 3T3 cells was assessed by the MTT assay. 32, 33 Exponentially growing cells (650 -1200/well) were plated in 50 L of media in 96-well microtiter plates. The outer wells of the plates were not used and were filled with 175 L of phosphate-buffered saline to provide added humidity. Plates were incubated for 24 hours at 37°C in 5% CO 2 . Medium (50 L) containing chlorambucil (Sigma) or melphalan (Sigma) was then added to six wells for each drug concentration, and plates were incubated for another 72 hours. Ara-C (Sigma) was added immediately after cells were plated, and plates were incubated for 96 hours. A total of 20 L of MTT (2.5 mg/mL in phosphate-buffered saline; Sigma) was then added to each well, and plates were incubated for 4 hours at 37°C. A total of 100 L of a solution consisting of 50% (vol/vol) N,N-dimethylformamide and 20% (wt/vol) sodium dodecyl sulfate (pH 4.7) was then added to the wells. Plates were wrapped in aluminum foil and returned to the incubator. On the following day, the formazan product formed by viable cells was quantified by measuring the absorbance at a wavelength of 570 nm, with a reference at 650 nm, on a microplate reader. The 50% inhibitory concentration (IC 50 ) was determined by plotting the percentage of surviving cells versus the log of drug concentration.
Growth inhibition assay
Exponentially growing cells (35,000/well) were plated in 6-well tissue culture plates in 3 mL of growth media containing either 1.0 M Ara-C, 10 M melphalan, a combination of both drugs at the same concentration, or no drug. At the end of a 96-hour exposure at 37°C in 5% CO 2 
Statistical analysis
Statistical analysis by Student's t test was performed using StatView 4.0 software (SAS Institute, Cary, NC).
RESULTS
To evaluate the feasibility of protecting cells from the combined toxicity of nitrogen mustards and cytosine nucleoside analogs, we have transduced 3T3 cells with a bicistronic retroviral vector coexpressing rat GST and human CD (Fig 1) . A portion of the transduced cells were then subjected to selection with 10 M Ara-C, a dose that is lethal for untransduced cells. The efficiency of gene transfer, enzyme activities, and drug sensitivity were then evaluated in transduced polyclonal cell populations, before and after Ara-C selection.
Gene transfer into 3T3 cells
The integrity of the vector sequences integrated in 3T3 cells was assessed by Southern blot analysis after digestion of genomic DNA with a restriction enzyme that cuts twice within the sequences of the MFG provirus backbone. Blots were then hybridized with a 32 P-labeled, full-length CD cDNA insert. This results in the detection of fragments of a predictable size, independent of the site of vector integration. Figure 2 shows the result of Southern blot analysis after SacI digestion. The expected 2.5-kb and 3.8-kb CD-containing fragments are seen in the DNA from 3T3 cells transduced with, respectively, the MFG/CD and MFG/GIC vectors. To determine the average copy number of transferred vectors in these cells, graded quantities of the MFG/CD plasmid corresponding to one, two, and five vector copies per cell were added to 10 g of genomic DNA from 3T3 cells before the digestion with the SacI restriction enzyme. Densitometric comparison of the signal intensity from the resulting CD-containing fragments revealed an average vector copy number per cell of ϳ1 and ϳ4 in the polyclonal populations of CD and GIC, respectively. After selection with 10 M Ara-C, the average vector copy number per cell increased to ϳ2 and ϳ5 in CD and GIC cells, respectively.
Peroxidase and CD enzyme activities of transduced 3T3 cells
Cytosolic extracts from cells transduced with GST, CD, or GIC vectors were assayed for CD and peroxidase activities, the latter being associated with the A3 subunit of GST (Table 1 ). In comparison with parent 3T3 or CD cells that had no detectable peroxidase activity, the peroxidase activity of cells transduced with GST and GIC vectors increased to ϳ32 U (nanomoles per minute per milligram of protein). After selection with Ara-C, the peroxidase activity of the GIC cells further increased Figure 2 . Southern blot analysis of transduced 3T3 cells. Genomic DNA was prepared from polyclonal populations transduced with either CD or GIC vectors. A total of 10 g from each sample was digested with SacI and migrated on a 1.0% agarose gel. After transfer to a nylon membrane, hybridization was performed with a 32 P-labeled, full-length CD cDNA probe as described in Materials and Methods. The expected fragment size is 2.5 kb for the CD vector and 3.8 kb for the GIC vector. Estimation of the copy number of CD-containing vectors was performed by adding graded amounts of pMFG-CD to 10 g of genomic DNA from 3T3 cells followed by digestion with SacI. MWM, molecular weight marker; CD and GIC, polyclonal NIH 3T3 cell populations transduced with CD and GIC vectors, respectively. CD(10A) and GIC(10A), NIH/CD and NIH/GIC cell populations selected with 10 M Ara-C.
2.6-fold, to 83 U (P Ͻ .001). The peroxidase activity of the CD cells increased minimally to 0.9 U after Ara-C selection. However, this minimal increase in peroxidase activity, which is most likely a nonspecific stress response, did not affect the resistance of CD cells to melphalan or chlorambucil (see below). As expected, transduction of 3T3 cells with the GST vector did not significantly alter their CD activity. In contrast, cells transduced with CD and GIC vectors showed approximately a 290-and 240-fold increase in CD activity, respectively, in comparison with parental 3T3 cells (P Ͻ .05). After selection with Ara-C, the CD activity of CD and GIC cells further increased 2.5-and 2.9-fold, respectively (P Ͻ .05), which is a 725-and 690-fold augmentation, respectively, in comparison with parental 3T3 cells.
Drug resistance of transduced 3T3 cells
Drug resistance studies on transduced 3T3 cells were performed using the MTT assay (Fig 3) . Drug resistance was evaluated by determining the IC 50 of a drug, which is defined as the concentration of drug that reduced the viability of the target cells by 50%. In comparison with parent 3T3 cells, GST cells were 2.6-and 3.7-fold more resistant to melphalan and chlorambucil, respectively (P Ͻ .001). Likewise, GIC cells were 2.3-and 3.4-fold more resistant to the same drugs (P Ͻ .0001). After selection with Ara-C, the resistance of GIC cells to melphalan and chlorambucil further increased 1.6-and 1.7-fold, respectively (P Ͻ .01), which is a 3.7-and 5.9-fold augmentation, respectively, when compared with parent 3T3 cells. As expected, the sensitivity of unselected CD cells to melphalan and chlorambucil remained unchanged. Intriguingly however, CD cells selected with Ara-C were 1.9-fold more sensitive to melphalan (P Ͻ .01), but not to chlorambucil, when compared with 3T3 cells.
3T3 cells transduced with CD and GIC vectors were 9.4-and 8.1-fold more resistant to Ara-C when compared with parental 3T3 cells (P Ͻ .01). Selection with Ara-C further increased their resistance to Ara-C by 4.1-and 6.5-fold, respectively (P Ͻ .05), corresponding to a 38.5-and 52.8-fold augmentation, respectively, when compared with parent 3T3 cells. As expected, the sensitivity of GST cells to Ara-C remained unchanged.
Resistance of transduced 3T3 cells to combination of melphalan and Ara-C To determine whether 3T3 cells transduced with GIC would be protected from simultaneous exposure to nitrogen mustards and cytosine nucleoside analogs, GIC cells were simultaneously exposed to 10 M melphalan and 1 M Ara-C. These drug concentrations, either Figure 2 .
†P Ͻ .05 for differences with 3T3 cells. ‡P Ͻ .05 for differences with parental transduced, unselected cells. Figure 3 . Drug sensitivity assays were performed using the MTT colorimetric assay as described in Materials and Methods. Results represent the mean IC 50 of five to six independent assays, with SE bars. Abbreviations are the same as in Figure 2 . a, P Յ .01 for differences with 3T3 cells; b, P Ͻ .05 for differences with transduced, unselected cells.
individually or in combination, completely inhibited the growth of parent 3T3 cells (Fig 4) . As expected, CD cells selected with Ara-C proliferated in the presence of Ara-C only. In contrast, GIC cells proliferated in the presence of either melphalan or Ara-C, as well as in the simultaneous presence of both drugs. The growth rate of GIC cells averaged 56% of that observed in the absence of drug when these cells were grown in the presence of Ara-C (P Ͻ .0001), 26% in the presence of melphalan (P Ͻ .001), and 18% in the simultaneous presence of both drugs (P Ͻ .01).
GIC cells selected with Ara-C displayed significantly more active growth in the simultaneous presence of melphalan and Ara-C. The growth rate of GIC cells selected with Ara-C averaged 94% of that observed in the absence of drug when these cells were grown in the presence of Ara-C, 33% in the presence of melphalan and 30% in the simultaneous presence of both drugs. Thus, after selection with Ara-C, the growth rate of GIC cells increased 1.7-fold (P Ͻ .05) in the presence of Ara-C alone or in the presence of a combination of both drugs. However, Ara-C selection of GIC cells failed to further increase their growth rate in the presence of melphalan in the growth assay (P ϭ .12).
Impact of melphalan selection on GIC-transduced cells
The impact of selection with a lethal dose of melphalan was assessed by measuring the enzyme activities of GIC cells selected with 25 M melphalan and their ability to grow in the simultaneous presence of 10 M melphalan and 1 M Ara-C.
Selection of GST and GIC polyclonal populations with melphalan increased their respective peroxidase activities to 60 U and 75 U, representing a 1.8-and 2.3-fold augmentation, respectively, in comparison with unselected cells (P Ͻ .001) ( Table 1) . Likewise, melphalan selection augmented the CD activity of GIC cells 1.9-fold (P Ͻ .05), which is a 450-fold increase when compared with parent 3T3 cells. Selection with melphalan also modestly augmented the CD activity of GST cells 4-fold when compared with parent 3T3 cells (P Ͻ .05). This result is rather intriguing because, unlike GST, CD expression has not been associated with a nonspecific stress response. Nevertheless, considering the levels of CD activity and Ara-C resistance obtained in CD and GIC cells, it is extremely unlikely that such a small increase in CD activity could have affected the resistance to Ara-C.
Melphalan-selected GIC cells also proliferated significantly more in the simultaneous presence of melphalan and Ara-C (Fig 4) . The growth rate of GIC cells selected with melphalan averaged 94% of that observed in absence of drug and in the presence of Ara-C, 59% in the presence of melphalan, and 50% in the simultaneous presence of both drugs. Thus, after melphalan selection, the growth rate of GIC cells increased 1.7-fold (P Ͻ .01) in the presence of Ara-C, 2.3-fold (P Ͻ .01) in the presence of melphalan, and 2.8-fold (P Ͻ .05) in the simultaneous presence of both drugs. In contrast, GST cells selected with melphalan grew in the presence of melphalan only. Although the growth rate of GIC cells in the simultaneous presence of melphalan and Ara-C was higher for cells selected with melphalan (50%) than for Ara-C-selected cells (30%), the difference observed was not significant (P ϭ .07).
DISCUSSION
We have previously demonstrated an increased resistance to nitrogen mustards in human leukemia cells and in murine fibroblast and bone marrow progenitor cells in vitro after retroviral gene transfer of rat GST. 17, 18 How- Other abbreviations are the same as in Figure 2 . a, P Յ .01 for differences with 3T3 cells; b, P Ͻ .05 for differences with GIC cells.
ever, we did not observe chemoprotection against chlorambucil in mice transplanted with bone marrow transduced with N2/GST virions (S.L., M.G., and D.C., unpublished results). A low copy number of vector (ϳ0.1 copy/cell) was present in bone marrow and spleen samples of mice at 6 months posttransplantation and after two treatments with chlorambucil. These results suggested that the moderate growth advantage conferred by GST expression from our vector might have been insufficient to increase the tolerance to chlorambucil in transplanted mice. To circumvent this problem, we have constructed a bicistronic vector coexpressing GST and CD. We have shown previously that CD confers a very strong survival advantage in favor of CD-transduced hematopoietic cells in vitro in the presence of Ara-C. 20 Moreover, we have demonstrated long-term expression of CD in hematopoietic tissues of CD-transplanted mice treated with Ara-C and an increased in vitro resistance to Ara-C in spleen and marrow cells derived from CD animals and expressing high levels of CD. 21 Taken together, these results suggest that ex vivo and/or in vivo Ara-C selection of transduced hematopoietic cells might be used to increase the representation of genetically modified cells in the hematopoietic system of transplanted mice. Thus, Ara-C selection might be used to increase the in vivo expression of a bicistronic GST-CD vector to achieve significant chemoprotection from the nitrogen mustards. This would be clinically significant in view of the broad spectrum of antineoplastic activity of these drugs. Furthermore, combining the expressions of GST and CD would broaden the spectrum of chemoprotection conferred by the vector by simultaneously increasing the hematopoietic tolerance to both alkylating agents and cytosine nucleoside analogs. In the present report, we demonstrate that retroviral gene transfer of GIC in murine fibroblast 3T3 cells confers in vitro resistance to nitrogen mustards and cytosine nucleoside analogs, as well as to the combination of both classes of drugs. Moreover, we show that selection of GIC cells with lethal doses of Ara-C or melphalan augments the level of resistance to both classes of drugs, regardless of whether they are used individually or in combination.
Southern blot analysis of genomic DNA confirmed the presence of unrearranged vector sequences in CD and GIC cells (Fig 2) . Densitometric comparison revealed the presence of a greater number of vector copies per cell in GIC cells than in CD cells, before and after Ara-C selection. Nevertheless, CD and GIC cells had comparable CD enzyme activities and Ara-C resistance before and after selection (Table 1 and Fig 3) , suggesting that the IRES-driven translation of CD in our bicistronic vector was reduced in comparison with the cap-dependent translation of the monocistronic vector. Others have observed such a relative decrease in IRES-driven translation. 23 Expression of functional GST enzyme in GIC cells was demonstrated by the increase in the peroxidase activity of these cells (Table 1) and by their resistance to melphalan and chlorambucil (Fig 3) . Likewise, functional expression of CD enzyme activity was evident in the increase in CD activity and resistance to Ara-C. The ability of our bicistronic vector to protect cells against the simultaneous exposure to nitrogen mustards and cytosine nucleoside analogs was shown by the growth of unselected GIC cells in the presence of Ara-C and melphalan at concentrations of drug that completely inhibited the growth of parental 3T3 cells (Fig 4) . The degree of growth suppression observed in the presence of both drugs was greater than that observed with either drug alone, suggesting an additive effect for the cytotoxicity of both drugs.
Importantly, we were able to select GIC cells with a dose of Ara-C that was lethal for untransduced cells, supporting the hypothesis that Ara-C selection might be used to increase the representation of GIC cells in the hematopoietic system of mice transplanted with GIC. Moreover, selection with Ara-C further increased the GST and CD enzyme activities (Table 1) , the resistance to melphalan, chlorambucil, and Ara-C (Fig 3) , and the growth rate of GIC cells exposed simultaneously to Ara-C and melphalan (Fig 4) . These results demonstrate that the expression of GST and CD increased after Ara-C selection. Taken together, the increase in vector copy number, enzyme activities, and drug resistance in CD and GIC cells selected with Ara-C suggests that exposure to a lethal dose of Ara-C resulted in the selection of transduced cells with higher levels of vector expression due to higher vector copy number and/or more transcriptionally active sites of vector integration.
We have also been able to select GIC cells with a dose of melphalan that was lethal for untransduced cells. Melphalan selection augmented the GST and CD enzyme activities of GIC cells to levels that were comparable with those obtained after selection with Ara-C ( Table 1 ). In addition, selection with melphalan also enhanced the growth rate of GIC cells in the presence of Ara-C or melphalan, as well as in the simultaneous presence of both drugs (Fig 4) . These results demonstrate that despite the moderate level of resistance conferred to nitrogen mustards by our bicistronic vector, it is possible to select GIC cells with a lethal dose of melphalan. Moreover, these results show that, similarly to selection with Ara-C, selection of GIC cells with melphalan increases the expression of GST and CD as well as the resistance to nitrogen mustards and cytosine nucleoside analogs, regardless of whether they are administered individually or in combination.
The combination of GST-and CD-mediated chemoprotection is of potential clinical interest because nitrogen mustards and cytosine nucleoside analogs are both used in the treatment of solid tumors and lymphomas. Chlorambucil and Ara-C are part of an effective regimen for the treatment of low-grade non-Hodgkin's lymphomas; 34 high-dose melphalan and high-dose Ara-C are both active in advanced non-Hodgkin's lymphomas; 35, 36 and finally, melphalan and gemcitabine are active against ovarian and breast cancers. [37] [38] [39] [40] In addition, Ara-C, a drug that inhibits DNA repair, has been reported to enhance the cytotoxic activity of melpha-lan. 41 Hence, conferring chemoprotection against the hematotoxicity produced by nitrogen mustards and cytosine nucleoside analogs could potentially allow the safe use of desirable drug combinations that might otherwise cause unacceptable hematopoietic toxicity.
Nitrogen mustards have been associated with an increased risk of the development of secondary neoplasms, principally acute leukemia. 42 Because resistance to nitrogen mustards has been shown to correlate with inhibition of DNA interstrand cross-link formation in rat mammary carcinoma cells overexpressing GST, 16 introduction of GST into bone marrow could possibly reduce the risk of developing secondary leukemia in patients treated with these agents. Selection of hematopoietic cells expressing GIC by nitrogen mustard would probably not be desirable because of the mutagenic and carcinogenic potentials of these drugs. However, selection with cytosine nucleoside analogs could potentially increase chemoprotection to nitrogen mustards and cytosine nucleoside analogs and decrease the risk of developing the secondary neoplasms that are associated with nitrogen mustard exposure.
In conclusion, we have shown that retroviral gene transfer of a bicistronic vector coexpressing rat GST and human CD conferred significant resistance to nitrogen mustards and cytosine nucleoside analogs in murine fibroblasts, permitting cell survival in the presence of a combination of both classes of drugs. Future experiments will evaluate the potential of combining GST and CD expression for in vivo chemoprotection from nitrogen mustards and cytosine nucleoside analogs in mice transplanted with GIC-transduced bone marrow.
